ClinicalTrials.gg
RecruitingNCT07552922DINGOUpdated Nov 18, 2026

Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1

An interventional study of Semi-structured Interview in Prostate Cancer (Adenocarcinoma), sponsored by St Vincent's Hospital, Sydney. Recruiting at 1 site in Australia. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by St Vincent's Hospital, Sydney · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 18, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 260 studies in Prostatic Neoplasms with a site in Australia — 70 open to participants now, 134 under way, 41 of them phase 3. Prostatic Neoplasms · Australia.

Planned enrollment
217th of 245
24 · median 232
Started
2025
with 27 others
No phase
19 of 260
4 open now
Primary completion
2027-05
later than 62 of 133 live
Registered
238th of 260
by date

Among the 260 studies in Prostatic Neoplasms with a site in Australia, this one is the 217th largest by planned enrollment of the 245 interventional ones that give a count, is one of 28 that started in 2025, is one of 19 with no phase, reaches primary completion later than 62 of the 133 other live ones, and was the 238th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

70 of the 260 studies in Prostatic Neoplasms with a site in Australia are open now. Recruiting first, the newest first:

64 more — sign in →

All 70 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Prostatic Neoplasms with a site in Australia, or all of them as a file.
02

Study summary

This study aims to explore the perceptions of men with prostate cancer (PCa) and high-risk biochemical recurrence (BCR) regarding the risk of breast-related side effects, including gynaecomastia, from treatment.

Read the detailed description

This study will inform a set of 'attributes' and their levels that can be used in a later discrete choice experiment (DCE), for which separate ethical approval will be sought, to assess the trade-offs patients are willing to make between breast-related side effects, other quality of life (QOL) impacts and cancer control.

03

Conditions studied

  • Prostate Cancer (Adenocarcinoma)

Keywords

  • gynaecomastia
  • prostate cancer
  • LHRH
  • testosterone
  • breast
  • estrogen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men with high-risk BCR PCa but no ADT+/-ARPI experience.
  • Men with ADT+/-ARPI experience who have experienced breast-related side effects from this treatment.

Exclusion criteria

Exclusion Criteria:

  • Men receiving psychiatric care as a consequence of their prostate cancer diagnosis or treatment thereof.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    A qualitative approach with semi-structured interviews.

    Through purposive sampling, we plan to conduct interviews with men from two groups: those with high-risk BCR PCa but no ADT+/-ARPI experience, and men with ADT+/-ARPI experience who have experienced breast-related side effects from this treatment. To inform an understanding of how perception of breast-related symptoms might inform treatment preferences, it is important to understand perspectives regarding the hypothetical risk of side-effects as well as those based on actual experience.

    Other: Semi-structured Interview

Interventions

  • OtherSemi-structured Interview

    this t study will use qualitative methods to explore men's views of gynaecomastia from high-risk BCR PCa treatments (Stage 1) to inform attributes and levels for a later DCE to examine patient treatment preferences (Stage 2).

06

What researchers measure

Primary outcomes

  1. Number and content of themes and subthemes describing PCa patients' perceptions of the risk of breast-related side effects, including gynaecomastia, from high-risk BCR PCa treatment.

    The outcome will be the set of themes and subthemes identified through qualitative analysis of semi-structured interviews. Interviews will be conducted with three groups: (1) men with high-risk BCR prostate cancer; (2) men with ADT ± ARPI experience; and (3) men who have experienced breast-related side effects from prostate cancer treatment.

    Time frame: 12 months

Secondary outcomes

  1. Number and content of discrete choice experiment (DCE) attributes and their levels, developed to assess the trade-offs patients are willing to make between breast-related side effects, other QoL impacts, and cancer control.

    The outcome will be a finalised set of attributes and levels for a DCE. Attributes and levels will be generated through semi-structured qualitative interviews with patients, analysed iteratively across participant groups, and refined with input from an advisory panel. A 'generator developed' approach will then be used to design the final set of attributes and levels for inclusion in the DCE.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for May 2027, 17 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 17 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion May 2026 → May 2027 and completion Nov 2026 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2025
First posted
Apr 27, 2026
StartActual
Dec 1, 2025
Primary completionEst.
May 30, 2027was May 2026
CompletionEst.
Nov 30, 2028was Nov 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 30, 2026→May 30, 2027
Nov 18, 2026
Study completion
Nov 30, 2026→Nov 30, 2028
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion May 30, 2026→May 30, 2027
    Study completion Nov 30, 2026→Nov 30, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07552922
Lead sponsor
St Vincent's Hospital, Sydney
Collaborators
University of Technology, Sydney
Responsible party
Anthony Joshua, FRACP (Medical Oncologist, St Vincent's Hospital, Sydney) — Principal investigator
First posted
Apr 27, 2026
Start date
Dec 1, 2025
Primary completion
May 30, 2027 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion